AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with a key data readout expected in Q3, potentially derisking the program. Partnered and proprietary pipeline programs lack momentum, with most assets preclinical or awaiting external funding, limiting near-term revenue visibility.